All In Biotech

Drug Trial Radar · NCT00617695

Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents

A Multicenter, Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study With Single-blind, Placebo-challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the Treatment of Acute Migraine Headache in Adolescents.

Last checked: Nov 20, 2026Latest source record: Oct 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

247

Actual

Start

Sep 2003

Primary completion

Not stated

Study completion Oct 2004

Sponsor

Lead sponsor
Impax Laboratories, LLCIndustry
Sponsor type
Industry
First posted
Feb 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches

Conditions

  • Migraine

Interventions

  • ZolmitriptanDrug

    5mg nasal spray

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Headache response and pain-free response to treatmentTime frame: 15 minutes, 30 minutes, 45 minutes, 1.5 hours and 2 hours after randomized treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.